Jean-Claude Bystryn 1938-2010. An obituary

被引：1

作者：

Grando, Sergei A. ^{[1
]}

Holubar, Karl ^{[3
]}

Schwartz, Robert A. ^{[2
]}

机构：

[1] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92697 USA

[2] New Jersey Med Sch Newark, Dept Dermatol, Newark, NJ USA

[3] Med Univ Vienna, Inst Hist Med, Vienna, Austria

来源：

EXPERIMENTAL DERMATOLOGY | 2011年 / 20卷 / 03期

关键词：

alopecia areata; intravenous immunoglobulin; melanoma vaccine; pemphigoid; pemphigus; vitiligo; INTRAVENOUS IMMUNOGLOBULIN THERAPY; MELANOMA-ASSOCIATED ANTIGENS; PEMPHIGUS VULGARIS ANTIGENS; BASAL-CELL SHRINKAGE; LUPUS-ERYTHEMATOSUS; ALOPECIA-AREATA; CIRCULATING AUTOANTIBODIES; VITILIGO ANTIBODIES; REGIONAL VARIATION; HUMAN SKIN;

D O I：

10.1111/j.1600-0625.2010.01214.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Jean-Claude Bystryn, M.D., passed away on 19 August, 2010. Dr. Bystryn's research interests encompassed a large group of dermatologic conditions. He has earned a worldwide recognition for his innovative works on autoimmune blistering diseases, melanoma and alopecia areata. The most significant impact Dr. Bystryn's research has made is on our understanding of the mechanisms of epidermal cell detachment (acantholysis) in pemphigus and development of adequate treatment. During the last decade, he chaired the Medical Advisory Board of the International Pemphigus and Pemphigoid Foundation. Dr. Bystryn was an innovative physician-scientist whose scientific contributions will be long recalled and admired both by patients and colleagues.

引用

页码：293 / 296

页数：4

共 50 条

[1] EPIDERMAL CYTOPLASMIC ANTIBODIES - INCIDENCE AND TYPE IN NORMAL PERSONS AND PATIENTS WITH MELANOMA [J].

ABEL, EA ;

BYSTRYN, JC .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1976, 66 (01) :44-48

[2] Tumid lupus erythematosus: Criteria for classification with immunohistochemical analysis [J].

Alexiades-Armenakas, MR ;

Baldassano, M ;

Bince, B ;

Werth, V ;

Bystryn, JC ;

Kamino, H ;

Soter, NA ;

Franks, AG .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (04) :494-500

[3]

BHAVANANDAN VP, 1980, J BIOL CHEM, V255, P5145

[4]

Bystryn J C, 1989, Immunol Ser, V46, P447

[5]

Bystryn J C, 1979, Am J Dermatopathol, V1, P325, DOI 10.1097/00000372-197900140-00006

[6]

Bystryn J C, 1995, Recent Results Cancer Res, V139, P337

[7] A novel explanation for acantholysis in pemphigus vulgaris: The basal cell shrinkage hypothesis [J].

Bystryn, JC ;

Grando, SA .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) :513-516

[8] IVIg treatment of pemphigus: How it works & how to use it [J].

Bystryn, JC ;

Rudolph, JL .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) :1093-1098

[9]

BYSTRYN JC, 1992, CANCER-AM CANCER SOC, V69, P1157, DOI 10.1002/cncr.2820690516

[10] DIRECT IMMUNOFLUORESCENCE STUDIES IN ALOPECIA-AREATA AND MALE PATTERN ALOPECIA [J].

BYSTRYN, JC ;

ORENTREICH, N ;

STENGEL, F .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1979, 73 (05) :317-320

← 1 2 3 4 5 →